Aug 13, 2020
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
Sep 29, 2019
Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Sep 29, 2019
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Sep 23, 2019
Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product
Sep 17, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer
Sep 10, 2019
HR Positive/ HER2 Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jul 30, 2019
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
May 24, 2019
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Nov 29, 2018
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Oct 19, 2018
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Jul 18, 2018
FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
Jun 03, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Feb 26, 2018
Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer
Dec 08, 2017
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Oct 12, 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Oct 06, 2017
Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio(TM) (abemaciclib) Plus NSAI in Advanced Breast Cancer